MDGL vs. VKTX

Last updated Apr 2, 2026

Compare and contrast key facts about Madrigal Pharmaceuticals, Inc. (MDGL) and Viking Therapeutics, Inc. (VKTX).

Performance

MDGL vs. VKTX - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Madrigal Pharmaceuticals, Inc. (MDGL) and Viking Therapeutics, Inc. (VKTX). The values are adjusted to include any dividend payments, if applicable.

MDGL vs. VKTX - Yearly Performance Comparison

	2026 (YTD)	2025	2024	2023	2022	2021	2020	2019	2018	2017
MDGL Madrigal Pharmaceuticals, Inc.	-9.02%	88.72%	33.36%	-20.28%	242.52%	-23.77%	22.02%	-19.17%	22.80%	516.04%
VKTX Viking Therapeutics, Inc.	-6.31%	-12.57%	116.23%	97.98%	104.35%	-18.29%	-29.80%	4.84%	88.42%	241.18%

Fundamentals

Market Cap MDGL : $11.89B VKTX : $3.76B
EPS MDGL : -$12.88 VKTX : -$3.19
PB Ratio MDGL : 19.72 VKTX : 5.88
Total Revenue (TTM) MDGL : $958.40M VKTX : $0.00
Gross Profit (TTM) MDGL : $902.26M VKTX : -$208.00K
EBITDA (TTM) MDGL : -$300.10M VKTX : -$393.01M

Returns By Period

In the year-to-date period, MDGL achieves a -9.02% return, which is significantly lower than VKTX's -6.31% return. Over the past 10 years, MDGL has outperformed VKTX with an annualized return of 50.73%, while VKTX has yielded a comparatively lower 36.57% annualized return.

MDGL

• 1D: 1.22%
• 1M: 21.63%
• YTD: -9.02%
• 6M: 17.97%
• 1Y: 63.54%
• 3Y*: 29.80%
• 5Y*: 34.90%
• 10Y*: 50.73%

VKTX

• 1D: 1.29%
• 1M: -1.14%
• YTD: -6.31%
• 6M: 20.42%
• 1Y: 37.85%
• 3Y*: 25.56%
• 5Y*: 39.32%
• 10Y*: 36.57%

*Multi-year figures are annualized to reflect compound growth (CAGR)

Return for Risk

MDGL vs. VKTX — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

MDGL

MDGL Risk / Return Rank: 78
MDGL Sharpe Ratio Rank: 82
MDGL Sortino Ratio Rank: 81
MDGL Omega Ratio Rank: 75
MDGL Calmar Ratio Rank: 77
MDGL Martin Ratio Rank: 74

VKTX

VKTX Risk / Return Rank: 59
VKTX Sharpe Ratio Rank: 58
VKTX Sortino Ratio Rank: 58
VKTX Omega Ratio Rank: 62
VKTX Calmar Ratio Rank: 59
VKTX Martin Ratio Rank: 59

The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

MDGL vs. VKTX - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Madrigal Pharmaceuticals, Inc. (MDGL) and Viking Therapeutics, Inc. (VKTX). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

	MDGL	VKTX	Difference
Sharpe ratio Return per unit of total volatility	1.40	0.48	+0.92
Sortino ratio Return per unit of downside risk	2.23	1.14	+1.09
Omega ratio Gain probability vs. loss probability	1.26	1.17	+0.09
Calmar ratio Return relative to maximum drawdown	2.04	0.81	+1.23
Martin ratio Return relative to average drawdown	4.47	1.79	+2.67
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month.

MDGL vs. VKTX - Sharpe Ratio Comparison

The current MDGL Sharpe Ratio is 1.40, which is higher than the VKTX Sharpe Ratio of 0.48. The chart below compares the historical Sharpe Ratios of MDGL and VKTX, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.

Sharpe Ratios by Period

	MDGL	VKTX	Difference
Sharpe Ratio (1Y) Calculated over the trailing 1-year period	1.40	0.48	+0.92
Sharpe Ratio (5Y) Calculated over the trailing 5-year period	0.26	0.39	-0.13
Sharpe Ratio (10Y) Calculated over the trailing 10-year period	0.43	0.37	+0.05
Sharpe Ratio (All Time) Calculated using the full available price history	0.03	0.12	-0.10

Correlation

The correlation between MDGL and VKTX is 0.38, which is considered to be low. This implies their price changes are not closely related. A low correlation is generally favorable for portfolio diversification, as it helps to reduce overall risk by spreading it across multiple assets with different performance patterns.

Dividends

MDGL vs. VKTX - Dividend Comparison

Neither MDGL nor VKTX has paid dividends to shareholders.

Tickers have no history of dividend payments

Drawdowns

MDGL vs. VKTX - Drawdown Comparison

The maximum MDGL drawdown since its inception was -98.40%, which is greater than VKTX's maximum drawdown of -90.41%. Use the drawdown chart below to compare losses from any high point for MDGL and VKTX.

Drawdown Indicators

	MDGL	VKTX	Difference
Max Drawdown Largest peak-to-trough decline	-98.40%	-90.41%	-7.99%
Max Drawdown (1Y) Largest decline over 1 year	-29.36%	-45.14%	+15.78%
Max Drawdown (5Y) Largest decline over 5 years	-61.41%	-78.86%	+17.45%
Max Drawdown (10Y) Largest decline over 10 years	-82.19%	-89.26%	+7.07%
Current Drawdown Current decline from peak	-12.11%	-65.12%	+53.01%
Average Drawdown Average peak-to-trough decline	-58.96%	-59.92%	+0.96%
Ulcer Index Depth and duration of drawdowns from previous peaks	13.43%	20.36%	-6.93%

Volatility

MDGL vs. VKTX - Volatility Comparison

The current volatility for Madrigal Pharmaceuticals, Inc. (MDGL) is 13.57%, while Viking Therapeutics, Inc. (VKTX) has a volatility of 17.70%. This indicates that MDGL experiences smaller price fluctuations and is considered to be less risky than VKTX based on this measure. The chart below showcases a comparison of their rolling one-month volatility.

Volatility by Period

	MDGL	VKTX	Difference
Volatility (1M) Calculated over the trailing 1-month period	13.57%	17.70%	-4.13%
Volatility (6M) Calculated over the trailing 6-month period	32.48%	45.64%	-13.16%
Volatility (1Y) Calculated over the trailing 1-year period	45.66%	78.45%	-32.79%
Volatility (5Y) Calculated over the trailing 5-year period, annualized	133.38%	101.67%	+31.71%
Volatility (10Y) Calculated over the trailing 10-year period, annualized	119.63%	98.98%	+20.65%

Financials